Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Withdrawn 1Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 17Carcinoma, Hepatocellular 5Recurrence 4Neoplasms, Plasma Cell 4Colorectal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Liver Neoplasms 3Sarcoma 2NSCLC 2Lymphoma, Large B-Cell, Diffuse 2Esophageal Neoplasms 2Waldenstrom Macroglobulinemia 1Stomach Neoplasms 1Pathologic Complete Response 1Osteosarcoma 1Neoplasms, Second Primary 1Neoplasms 1Melanoma 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Large Granular Lymphocytic 1Leiomyosarcoma 1Kidney Neoplasms 1Immunoglobulin Light-chain Amyloidosis 1Immunoblastic Lymphadenopathy 1Glioblastoma 1Extrapancreatic Neuroendocrine Tumor 1Colonic Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 37Etoposide 25Vincristine 24Cytarabine 21Doxorubicin 19Rituximab 17Radiotherapy 17Peripheral Blood Stem Cell Transplantation 16Melphalan 16Prednisolone 14Methotrexate 14Filgrastim 13fludarabine phosphate 11Prednisone 11Dexamethasone 11Carmustine 9Bleomycin 9pegylated granulocyte colony-stimulating factor 8Cyclosporine 8Busulfan 8fludarabine 7Ifosfamide 7Cisplatin 7sargramostim 6Vinblastine 6Mitoxantrone 6Methylprednisolone 6Gemcitabine 6Chlorambucil 6Antilymphocyte Serum 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Lymphoma × Thalidomide × Clear all
NCT00958854 2013-08-26

Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma

National Cancer Institute (NCI)

Phase 2 Unknown
37 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡